Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 234-933-1 | CAS number: 12042-91-0
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Repeated dose toxicity, oral route: NOAEL = 1000 mg/kg bw/d (analogue substance, OECD 422, Key, rel.2), corresponding to a ca. NOAEL of 290 mg/kg bw/day for Dialuminium chloride penntahydroxide
Repeated dose toxicity, inhalation : LOAEL = 15.3 mg/m3 (OECD 413, Key, rel.2)
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Link to relevant study records
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 11 September 2006 - 03 November 2006
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- guideline study with acceptable restrictions
- Remarks:
- Study was conducted according to OECD guideline 422 and under GLP conditions.
- Reason / purpose for cross-reference:
- reference to same study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test)
- Deviations:
- no
- Principles of method if other than guideline:
- Not relevant
- GLP compliance:
- yes
- Limit test:
- no
- Specific details on test material used for the study:
- - Stability under test conditions: At least 48 hours
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Deutschland, Sulzfeld, Germany
- Age at study initiation:
Males: approx. 9 weeks
Females: approx. 11 weeks
- Weight at study initiation: All animals within +/- 20% of the sex mean
- Fasting period before study:
- Housing:
Pre-mating: groups of 5 animals/sex/cage
Mating: 1 male, 1 female
Post-mating: males in groups of 5 animals/sex/cage, females individually
Lactation: offspring together with dam
- Diet (e.g. ad libitum): Ad libitum, pelleted rodent diet
- Water (e.g. ad libitum): Ad libitum, tap-water
- Acclimation period: 4 days prior to start of treatment
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 19.9-23.4
- Humidity (%): 37-95
- Air changes (per hr): 15
- Photoperiod (hrs dark / hrs light): 12/12 - Route of administration:
- oral: gavage
- Vehicle:
- water
- Details on oral exposure:
- PREPARATION OF DOSING SOLUTIONS:
Formulations (w/w) were prepared within 4 hours prior to dosing and were homogenised to a visually acceptable level. Adjustment was made for specific gravity of the test substance. No adjustment was made for specific gravity of the vehicle and formulation.
VEHICLE
- Justification for use and choice of vehicle (if other than water): Water
- Concentration in vehicle: ?
- Amount of vehicle (if gavage): 5 ml/kg bw - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Formulated samples were analysed using ICP-MS
- Duration of treatment / exposure:
- Males: 28 days
Females: 37 to 53 days (because of developmental purpose of study) - Frequency of treatment:
- Once daily, 7 days a week
- Dose / conc.:
- 40 mg/kg bw/day (actual dose received)
- Remarks:
- actual ingested
- Dose / conc.:
- 200 mg/kg bw/day (actual dose received)
- Remarks:
- actual ingested
- Dose / conc.:
- 1 000 mg/kg bw/day (actual dose received)
- Remarks:
- actual ingested
- Dose / conc.:
- 3.6 mg/kg bw/day (actual dose received)
- Remarks:
- actual ingested Aluminium
- Dose / conc.:
- 18 mg/kg bw/day (actual dose received)
- Remarks:
- actual ingested Aluminium
- Dose / conc.:
- 90 mg/kg bw/day (actual dose received)
- Remarks:
- actual ingested Aluminium
- No. of animals per sex per dose:
- 10
- Control animals:
- yes, concurrent no treatment
- Details on study design:
- - Dose selection rationale: Based on the results of a dose range finding study (NOTOX project 473524)
- Rationale for animal assignment (if not random): Random
- Section schedule rationale (if not random): Not data - Positive control:
- Not relevant
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: At least twice daily
- Cage side observations checked: Mortality/viability
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: At least once daily
BODY WEIGHT: Yes
- Time schedule for examinations: At start, once weekly and at death (females also at: gestation days 0, 4, 7, 11, 17, 20, lactation day 1, 4)
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study):
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes, weekly
- Compound intake calculated as time-weighted averages from the consumption and body weight gain data: No
WATER CONSUMPTION: No, not recorded, only subjective appraisal
OPHTHALMOSCOPIC EXAMINATION: No
HAEMATOLOGY: Yes
- Time schedule for collection of blood: Immediately prior to scheduled post mortem examination
- Anaesthetic used for blood collection: Yes (Isoflurane)
- Animals fasted: Yes, max. 20 hours overnight
- How many animals: 5 males and 5 females randomly selected from each group
- Parameters checked: see "Any other information on materials and methods incl. tables"
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: Immediately prior to scheduled post mortem examination
- Animals fasted: Yes, max. 20 hours overnight
- How many animals: 5 males and 5 females randomly selected from each group
- Parameters checked: see "Any other information on materials and methods incl. tables"
URINALYSIS: No
NEUROBEHAVIOURAL EXAMINATION: Yes
- Time schedule for examinations: Males during week 4, females during lactation
- Dose groups that were examined: 5 males and 5 females, randomly selected from all groups
- Battery of functions tested: hearing ability / pupillary reflex / static righting reflex / grip strength / motor activity test - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes, of all organs of all animals
HISTOPATHOLOGY: Yes, examination of following organs from 5 animals/sex/group: see "Any other information on materials and methods incl. tables" - Other examinations:
- Not relevant
- Statistics:
- - Variables with normal distribution: Dunnett-test based on a pooled variance estimate was applied for the comparison of the treated groups and the control groups for each sex
- The steel-test was applied if the data was not assumed to follow a normal distribution
- The Fisher Exact-test was applied to frequency data
All tests were two-sided and in all cases p<0.05 was accepted as the lowest level of significance.
No statistical analysis performed on histopathology findings.
Test statistics were calculated on the basis of exact values for means and pooled variances. - Clinical signs:
- no effects observed
- Description (incidence and severity):
- No clinical signs of toxicity noted.
Incidental findings that were noted consisted of salivation and alopecia of various body parts. These findings are commonly noted in rats of this age and strain which are housed and treated under the conditions in this study.
No clinical signs were noted in control males, males at 40 mg/kg bw/day and in both sexes at 200 mg/kg bw/day. - Mortality:
- no mortality observed
- Description (incidence):
- One female sacrificed in extremis due to parturition difficulties on day 22 p.c.
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- Slightly lower mean bw for females at 1000 mg/kg bw/d at day 8 with slight weight loss for three of these females.
BW recovered during the following mating and post-coital period. In the other groups no deviations compared to controls - Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- Mean food consumption of females at 1000 mg/kg bw/d slightly lower than controls. Otherwise no deviations compared to controls
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Description (incidence and severity):
- Not performed
- Haematological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Minor, but statistically significant lowering of MCHC in M and F of 1000 mg/kg bw/g group
Minor, but statistically significant higher plateled count in males at 1000 mg/kg bw - Clinical biochemistry findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Males at 1000 mg/kg bw/d: statistically significant
-lower ALP activity
-lower albumin levels
-higher Potassium levels
-higher inorganic phospate levels
No deviations in females or in males at 40 & 200 mg/kg/d - Urinalysis findings:
- not examined
- Behaviour (functional findings):
- no effects observed
- Description (incidence and severity):
- All parameters (hearing ability, pupillary reflex, static righting reflex and grip strength) were normal in all animals.
The variation in motor activity did not indicate a relation with treatment - Organ weight findings including organ / body weight ratios:
- no effects observed
- Description (incidence and severity):
- Minor changes in brain weight of females at 1000 mg/kg and kidney weight of females at 200 mg/kg were not considered to be relevant or substance-related.
- Gross pathological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Red foci on glandular mucosa of the stomach in 5/10 males at 1000 mg/kg/day, with thickening of glandular mucosa or limiting ridge in two of these five.
No other relevant abnormalities were seen except coagulum in the caecum and enlargement of liver and spleen in the control F sacrificed in extremis.
Incidental findings were considered changes of no toxicological significance.
No macroscopic abnormalities were noted among M at 200 mg/kg bw/d and F at 1000 mg/kg bw/d - Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- Mild to moderate subacute inflammation of the glandular mucosa and minimal to moderate superficial easinophilic spheroids in all examined animals of both sexes at 1000 mg/kg bw/d
- Histopathological findings: neoplastic:
- not examined
- Dose descriptor:
- NOAEL
- Remarks:
- Local effects
- Effect level:
- 200 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male
- Basis for effect level:
- other: Local effects (stomach) at 1000 mg/kg bw/day
- Dose descriptor:
- NOAEL
- Remarks:
- Local effects
- Effect level:
- 18 mg/kg bw/day (actual dose received)
- Based on:
- act. ingr.
- Remarks:
- Al 3+
- Sex:
- male
- Basis for effect level:
- other: Local effects (stomach) at 90 mg Al/kg bw/day
- Dose descriptor:
- LOAEL
- Remarks:
- Local effects
- Effect level:
- 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male
- Basis for effect level:
- other: Local effects (stomach) at 1000 mg /kg bw/day
- Dose descriptor:
- LOAEL
- Remarks:
- Local effects
- Effect level:
- 90 mg/kg bw/day (actual dose received)
- Based on:
- act. ingr.
- Remarks:
- Al 3+
- Sex:
- male
- Basis for effect level:
- other: Local effects (stomach) at 90 mg Al/kg bw/day
- Dose descriptor:
- NOAEL
- Remarks:
- Systemic effects
- Effect level:
- 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male
- Basis for effect level:
- clinical biochemistry
- gross pathology
- haematology
- histopathology: non-neoplastic
- Dose descriptor:
- NOAEL
- Remarks:
- systemic effects
- Effect level:
- 90 mg/kg bw/day (actual dose received)
- Based on:
- act. ingr.
- Remarks:
- Al 3+
- Sex:
- male
- Basis for effect level:
- clinical biochemistry
- gross pathology
- haematology
- histopathology: non-neoplastic
- Dose descriptor:
- NOAEL
- Remarks:
- Local and systemic effects
- Effect level:
- 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- female
- Basis for effect level:
- histopathology: non-neoplastic
- Dose descriptor:
- NOAEL
- Remarks:
- Local and systemic effects
- Effect level:
- 90 mg/kg bw/day (actual dose received)
- Based on:
- act. ingr.
- Remarks:
- Al 3+
- Sex:
- female
- Basis for effect level:
- histopathology: non-neoplastic
- Critical effects observed:
- not specified
- Conclusions:
- In a combined repeated dose / reproductive screening study (OECD 422), administration of Aluminium chloride basic by oral gavage to male and female rats at dose levels of 40, 200 or 1000 mg/kg/d (equivalent to 3.6, 18 and 90 mg/kg bw/d Al3+) was studied. No toxic effects were observed in females at any dose. Therefore, the overall NOAEL for female rats was established to be 1000 mg/kg bw/day for Aluminium chloride basic (equivalent to 90 mg/kg bw/d Al3+). For males the NOAEL for local effects was established to be 200 mg/kg bw/day (equivalent to 18 mg/kg bw/d Al3+) and for systemic toxicity 1000 mg/kg bw/day (equivalent to 90 mg/kg bw/d Al3+).
- Executive summary:
A combined repeated dose / reproductive screening study (OECD 422), studied the administration of Aluminium chloride basic by oral gavage to male and female Wistar rats at dose levels of 40, 200 or 1000 mg /kg/d (equivalent to 3.6, 18 and 90 mg/kg bw/d Al3+). 10 animals/sex/group were used. Males were exposed for 28 days, females between 37 -53 days (because of developmental toxicity purpose of study). Detailed clinical signs, body weight, food consumption, water consumption (subjective appraisal), haematology, clinical chemistry, neurobehaviour and gross and histopathology were studied.
Slightly lower mean bodyweight was observed for females at the 1000 mg/kg bw/day (equivalent to 90 mg /kg bw/d Al3+) group at day 8, with slight weight loss for three of these females.
Bodyweight recovered during the following mating and post-coital period. In the other groups no deviations were observed as compared to controls.
Mean food consumption of females at 1000 mg/kg bw/day (equivalent to 90 mg/kg bw/d Al3+) was slightly lower than controls. Otherwise no deviations were observed as compared to controls.
Minor, but statistically significant lowering of MCHC was observed in males and females of the 1000 mg/kg bw/day (equivalent to 90 mg/kg bw/d Al3+) group.
Minor, but statistically significant higher plateled count was observed in males at a dose of 1000 mg/kg bw (equivalent to 90 mg/kg bw/d Al3+).
Males at 1000 mg/kg bw/day had statistically significant lower ALP activity, lower albumin levels, higher Potassium levels, higher inorganic phospate levels. No deviations were observed in females or in males and females at a dose of 40 & 200 mg/kg/d (equivalent to 3.6 and 18 mg/kg bw/d Al3+).
Red foci on glandular mucosa of the stomach were observed in 5 of 10 males at a dose of 1000 mg/kg/day (equivalent to 90 mg/kg bw/d Al3+), with thickening of glandular mucosa or limiting ridge in two of these five. No other relevant abnormalities were seen.
Mild to moderate subacute inflammation of the glandular mucosa and minimal to moderate superficial easinophilic spheroids was observed in all examined animals of both sexes at 1000 mg/kg bw/day (equivalent to 90 mg/kg/d Al3+).
Based on these results, the overall NOAEL for female rats was established to be 1000 mg/kg bw/day (equivalent to 90 mg/kg/d Al3+).
For males the NOAEL for local effects was established to be 200 mg/kg bw/day and for systemic toxicity 1000 mg/kg bw/day (equivalent to 90 mg/kg/d Al3+). In a combined repeated dose / reproductive screening study, administration of Aluminium chloride basic by oral gavage to male and female rats at dose levels of 20, 200 or 1000 mg /kg/d from two weeks prior to mating to at least 3 days of lactation (females) or 28 days (males) revealed no toxicity in females at any dose.
The NOAEL for local (stomach) toxicity in males is 200 mg/kg bw/d (equivalent to 18 mg Al3+)
The LOAEL for local (stomach) toxicity in males is 1000 mg/kg bw/d (equivalent to 90 mg Al3+)
The NOAEL for systemic toxicity in males is 1000 mg/kg bw/d (equivalent to 90 mg/kg/d Al3+).
The NOAEL for local and systemic toxicity in females is 1000 mg/kg bw/d (equivalent to 90 mg/kg/d Al3+).
Reference
Not relevant
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 290 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
- Quality of whole database:
- No study was available on dialuminium chloride pentahydroxide. A read-across approach was followed with a key study performed on aluminium chloride, basic according to the OECD Guideline No. 422.
Repeated dose toxicity: inhalation - systemic effects
Link to relevant study records
- Endpoint:
- sub-chronic toxicity: inhalation
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 29 June 1972 - 26 September 1972
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- comparable to guideline study with acceptable restrictions
- Remarks:
- Study was conducted before the introduction of GLP and not according to an OECD guideline. However, the study has a proper design and the report is concise.
- Reason / purpose for cross-reference:
- reference to same study
- Reason / purpose for cross-reference:
- reference to same study
- Reason / purpose for cross-reference:
- reference to same study
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 413 (Subchronic Inhalation Toxicity: 90-Day Study)
- Deviations:
- yes
- Remarks:
- Pre-guideline study
- Principles of method if other than guideline:
- Not relevant
- GLP compliance:
- no
- Remarks:
- pre-GLP study
- Limit test:
- yes
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Route of administration:
- inhalation: aerosol
- Type of inhalation exposure:
- whole body
- Remarks:
- (exposure room of 10 m3)
- Vehicle:
- other: unchanged (no vehicle)
- Remarks on MMAD:
- MMAD / GSD: No data
- Analytical verification of doses or concentrations:
- no
- Duration of treatment / exposure:
- 65 seconds (1x10 and 11x5 seconds) in 6 hours on exposure days
- Frequency of treatment:
- 65 times in 90 days
- Dose / conc.:
- 15.3 mg/m³ air (nominal)
- Remarks:
- Doses / Concentrations:
Deodorant spray, 9.0% Aluminiumhydroxichlorid
Basis:
nominal conc. - No. of animals per sex per dose:
- 10
- Control animals:
- yes, concurrent no treatment
- Mortality:
- mortality observed, non-treatment-related
- Description (incidence):
- One male rat died after 62 days of inhalation without clear symptoms
- Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- No adverse effects were observed on body weight
- Haematological findings:
- no effects observed
- Description (incidence and severity):
- No adverse effects were observed on blood as well as albumine/globuline in blood and enzyme activities
- Urinalysis findings:
- no effects observed
- Description (incidence and severity):
- No adverse effects were observed urine
- Description (incidence and severity):
- Organ weights were normal.
- Gross pathological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Macro and microscopic examination: All animals in the test group showed moderate phagocytose in the lungs and small dust spread into lymph peribronchial lymph nodes.
- Dose descriptor:
- LOAEC
- Effect level:
- 15.3 mg/m³ air (nominal)
- Based on:
- other: Deodorant spray, 9.0% Aluminiumhydroxichlorid
- Sex:
- male/female
- Basis for effect level:
- other: Moderate phagocytose in the lungs and small dust spread into lymph peribronchial lymph nodes
- Critical effects observed:
- not specified
- Conclusions:
- LOAEC = 15.3 mg/m3. Some pathological effects were found: All animals in the test group showed moderate phagocytose in the lungs and small dust spread into lymph peribronchial lymph nodes at the tested concentration and under the conditions of this study.
- Executive summary:
The effects of 90-day exposure of rats to deodorant spray containing 9% aluminiumhydroxychloride was tested in this inhalation study. 10 male and 10 female rats were exposed, while another 10 males and females formed the control group.
Clinical signs, body weights, blood and urine and macro and microscopic abnormalities were recorded.
One male rat died after 62 days of inhalation without clear symptoms. No adverse effects were observed on body weight, blood and urine, as well as albumine/globuline in blood and enzymeactivities. Organ weights were also normal.
Macro and microscopic examination showed moderate phagocytose in the lungs and small dust spread into lymph peribronchial lymph nodes in all animals.
A LOAEC of 15.3 mg/m3 could be established (only concentration tested).
Reference
The daily amount of deodorant sprayed averaged 121.6 g. In the course of 90 days, in total 7785 g of product was sprayed .The entire Locron P consumption is therefore about 700 g. The concentration of deodorant in the exposure room was approximately 170 mg/m3 in the first 10 seconds of the first exposure. It is unclear what the average exposure concentration of test substance was.
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LOAEC
- 15.3 mg/m³
- Study duration:
- subchronic
- Species:
- rat
- Quality of whole database:
- Pre-GLP study well conducted following a similar method to the OECD guideline No. 413.
Repeated dose toxicity: inhalation - local effects
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
Repeated dose toxicity: dermal - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
Repeated dose toxicity, Oral
A key study was identified (Beekhuijzen, 2007). In this combined repeated dose / reproductive screening study (OECD 422), the analogue substance Aluminium chloride basic is administered by oral gavage to male and female Wistar rats at dose levels of 20, 200 or 1000 mg /kg bw/d corresponding to 3.6, 18, 90 mg Al3+/kg bw/day. Ten animals/sex/group were used. Males were exposed for 28 days, females between 37-53 days (because of developmental toxicity purpose of study). Detailed clinical signs, body weight, food consumption, water consumption (subjective appraisal), haematology, clinical chemistry, neurobehaviour and gross and histopathology were studied.
From two weeks prior to mating to at least 3 days of lactation (females) or 28 days (males) revealed no systemic toxicity was observed up to the highest dose (1000 mg/kg bw/d).
NOAEL(oral, combined, systemic effects) = 1000 mg/kg bw/d (equivalent to 90 mg/kg bw/d Al3+)
Based on the read-across approach, NOAEL(Dialuminium chloride pentahydroxide) = ca. 290 mg/kg bw/day
Repeated dose toxicity, Dermal
No study was available but no systemic effects were observed in acute dermal toxicity, skin irritation or skin sensitisation studies.
Repeated dose toxicity, Inhalation
A key stsudy was identified (Weigand, 1973). The effects of 90-day exposure of rats to deodorant spray containing 9% aluminiumhydroxychloride was tested in this inhalation study. 10 male and 10 female rats were exposed, while another 10 males and females formed the control group.
Clinical signs, body weights, blood and urine and macro and microscopic abnormalities were recorded.
One male rat died after 62 days of inhalation without clear symptoms. No adverse effects were observed on body weight, blood and urine, as well as albumine/globuline in blood and enzymeactivities. Organ weights were also normal.
Macro and microscopic examination showed moderate phagocytose in the lungs and small dust spread into lymph peribronchial lymph nodes in all animals.
LOAEC(inhalation) = 15.3 mg/m3
Justification for classification or non-classification
Harmonized classification:
The test material has no harmonized classification according to the Regulation (EC) No 1272/2008.
Self-classification:
Based on the available data, no self-classification is proposed regarding the specific target organ toxicity after oral dose-repeated exposure and after inhalation-repeated dose exposure according to the Annex VI of the Regulation (EC) No. 1272/2008 (CLP) and to the GHS.
There were no data regarding the dermal route.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.